Iron Deficiency Drives Dopaminergic Hypersensitivity in Rodent Restless Legs Model

The Neurological Intersection of Iron Deficiency and Restless Legs

Restless Legs Syndrome is a prevalent sensorimotor disorder affecting approximately 3% of the general adult population (95% CI 1.4% to 3.8%), often resulting in profound sleep disruption and diminished quality of life [1]. While the condition is frequently associated with systemic iron deficiency, many patients exhibit normal peripheral iron markers despite having low iron concentrations in the central nervous system, particularly within the substantia nigra, a midbrain structure critical for motor control [2, 3]. Clinical management remains challenging, as many patients eventually develop refractory symptoms that no longer respond to standard therapy or suffer from augmentation, where symptoms worsen due to long-term dopaminergic treatment [4, 5]. Current evidence-based guidelines emphasize the role of brain iron dysregulation in the pathogenesis of the disease, yet the precise downstream effects on neural signaling remain incompletely understood [6, 7]. A new study utilizing a rodent model of brain iron deficiency now identifies increased dopaminergic sensitivity within the striatal-entopeduncular pathway, a neural circuit connecting the striatum to the internal segment of the globus pallidus, as a potential driver of these symptoms [8].

Mapping the Striatal-Entopeduncular Circuit

The researchers hypothesized that Restless Legs Syndrome and the restlessness observed during opioid withdrawal share common neurobiological mechanisms, a theory supported by the clinical efficacy of mu-opioid receptor (MOR) agonists in treating the disorder. This connection is further evidenced by the observation that patients undergoing opioid withdrawal frequently exhibit a phenotype nearly identical to Restless Legs Syndrome. Specifically, the study proposed that both conditions involve an increased sensitivity of striatal striosomal neurons, which are specialized nerve cell clusters that co-express mu-opioid receptors and dopamine D1 receptors (D1Rs). These striosomal neurons are responsible for releasing gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the central nervous system, into the internal segment of the globus pallidus (GPi), a major output nucleus of the basal ganglia that regulates voluntary movement. To test this circuit-specific hypothesis, the researchers conducted fiber-photometry experiments, a technique that uses light to measure fluorescent signals from sensors in the brain, in mice with diet-induced brain iron deficiency (BID). They utilized a viral GABA biosensor, a genetically engineered protein that fluoresces when it binds to GABA, which was injected into the entopeduncular nucleus (EPN). The entopeduncular nucleus serves as the rodent equivalent of the human internal segment of the globus pallidus. By monitoring the entopeduncular nucleus in real time, the study aimed to quantify how brain iron deficiency alters the signaling dynamics of the opioid-responsive striatal-entopeduncular pathway, potentially identifying the physiological driver of the motor restlessness seen in clinical practice.

Dopaminergic Hypersensitivity and GABAergic Response

To evaluate the functional consequences of iron depletion on neural signaling, the researchers utilized a rodent model of Restless Legs Syndrome established through diet-induced brain iron deficiency (BID). The study focused on the striatal-entopeduncular pathway by measuring the release of gamma-aminobutyric acid (GABA) within the entopeduncular nucleus (EPN). Following the systemic administration of SKF81297, a dopamine D1 receptor (D1R) agonist, which is a pharmacological agent that selectively binds to and activates D1 receptors, the team employed fiber-photometry to monitor real-time neurochemical changes. This approach allowed the investigators to quantify how iron-deficient circuits respond to dopaminergic stimulation compared to iron-sufficient controls. The experimental data revealed a distinct physiological shift in the iron-deficient mice. A minimal locomotor-activating dose of SKF81297 induced a significant release of GABA in the entopeduncular nucleus of mice with brain iron deficiency, while the same dose failed to elicit a response in the control group. When the researchers analyzed locomotor activation, referring to the physical movement and ambulatory activity of the subjects, they found that this neurochemical hypersensitivity correlated with increased physical restlessness. These findings indicate that brain iron deficiency significantly lowers the threshold for dopaminergic activation within the striatal-entopeduncular circuit. For the clinician, this suggests that the motor symptoms of Restless Legs Syndrome may stem from an exaggerated GABAergic output in response to endogenous dopamine, providing a potential physiological explanation for the characteristic urge to move that defines the disorder.

Opioid Modulation of Striatal Signaling

To investigate the therapeutic mechanisms of opioid agonists in Restless Legs Syndrome, the researchers measured gamma-aminobutyric acid (GABA) release in the entopeduncular nucleus following the systemic administration of methadone, a mu-opioid receptor (MOR) agonist. In the rodent model of brain iron deficiency, the investigators observed that a maximal locomotor-activating dose of methadone significantly reduced GABA release in the entopeduncular nucleus after the administration of saline. This inhibitory effect remained robust even when the circuit was pharmacologically stimulated with dopamine; the same maximal dose of methadone significantly reduced entopeduncular GABA release in mice with brain iron deficiency after the administration of the dopamine D1 receptor agonist SKF81297. These findings demonstrate that mu-opioid receptor activation can directly suppress the pathological GABAergic overactivity triggered by iron depletion, providing a neurobiological basis for why opioid agonists effectively suppress the motor restlessness associated with both Restless Legs Syndrome and opioid withdrawal. The study further characterized the molecular landscape of the striatum by analyzing the messenger RNA (mRNA) expression of dopamine D1 receptors, mu-opioid receptors, and adenosine A1 receptors (A1Rs), which are G-protein coupled receptors that typically inhibit neurotransmitter release. The researchers found that brain iron deficiency was associated with a significant reduction in the striatal expression of mu-opioid receptors, as well as a significant reduction in the striatal expression of adenosine A1 receptors. This downregulation of inhibitory receptors suggests that iron deficiency creates a state of disinhibition within the striatal-entopeduncular pathway. For the practicing physician, these data indicate that the pathophysiology of Restless Legs Syndrome involves more than just dopaminergic fluctuations; it represents a complex failure of endogenous inhibitory systems. The reduction in mu-opioid and adenosine receptor expression likely contributes to the hypersensitivity of the circuit, explaining why exogenous agonists are required to compensate for the diminished regulatory capacity of the iron-deficient brain.

Clinical Implications for Refractory Restlessness

The results of this study indicate that brain iron deficiency induces an increased dopaminergic sensitivity of the opioid-responsive striatal-entopeduncular nucleus pathway. This specific circuit, which connects the striatum to the rodent equivalent of the internal segment of the globus pallidus, appears to be a primary site of neurobiological dysfunction. By demonstrating that a minimal locomotor-activating dose of the dopamine D1 receptor agonist SKF81297 triggered significant gamma-aminobutyric acid (GABA) release in the entopeduncular nucleus of iron-deficient mice but not in controls, the researchers have identified a clear link between iron status and dopamine-driven motor activity. For the clinician, this provides a mechanistic explanation for why patients with Restless Legs Syndrome often exhibit an exaggerated response to dopaminergic stimuli, while also clarifying the role of iron in maintaining normal motor circuit thresholds. This pathway hypersensitivity might represent a pivotal pathogenetic mechanism of the restlessness of Restless Legs Syndrome and opioid withdrawal, suggesting that these two clinically similar conditions share a common neurobiological substrate. The finding that the mu-opioid receptor agonist methadone significantly reduced GABA release in the entopeduncular nucleus, even after dopamine-induced stimulation, underscores the therapeutic potential of targeting this circuit. Because brain iron deficiency was also associated with a significant reduction in the striatal expression of mu-opioid receptors and adenosine A1 receptors, which are inhibitory receptors that normally dampen neuronal activity, the circuit becomes doubly vulnerable to disinhibition. This suggests that in refractory cases where standard dopaminergic therapy fails or leads to augmentation, the underlying issue may be this profound circuit-level hypersensitivity. Understanding this mechanism allows for a more targeted approach to treatment, emphasizing the use of mu-opioid receptor agonists to directly suppress the overactive striatal-entopeduncular output that drives the clinical manifestation of restlessness.

References

1. Broström A, Alimoradi Z, Lind J, Ulander M, Lundin F, Pakpour AH. Worldwide estimation of restless legs syndrome: a systematic review and meta‐analysis of prevalence in the general adult population. Journal of Sleep Research. 2023. doi:10.1111/jsr.13783

2. Zalpuri S, Schotten N, Baart A, Watering L, Hurk K, Kraaij M. Iron deficiency–related symptoms in whole blood donors: a systematic review. Transfusion. 2019. doi:10.1111/trf.15509

3. Allen RP, Picchietti DL, Auerbach M, et al. Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report.. Sleep medicine. 2018. doi:10.1016/j.sleep.2017.11.1126

4. Thrash GW, Wang E, Brockington D, et al. Neuromodulation for Restless Legs Syndrome: A Systematic Review and Mechanistic Considerations for Spinal Cord Stimulation. Sleep And Breathing. 2026. doi:10.1007/s11325-026-03638-7

5. Safarpour Y, Vaziri ND, Jabbari B. Restless Legs Syndrome in Chronic Kidney Disease- a Systematic Review. Tremor and Other Hyperkinetic Movements. 2023. doi:10.5334/tohm.752

6. Yang X, Yang B, Ming M, et al. Efficacy and tolerability of intravenous iron for patients with restless legs syndrome: evidence from randomized trials and observational studies.. Sleep Medicine. 2019. doi:10.1016/J.SLEEP.2019.01.040

7. Chmiel J, Kurpas D. Neural Correlates of Restless Legs Syndrome (RLS) Based on Electroencephalogram (EEG)—A Mechanistic Review. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262110675

8. Valle-León M, Rea W, Quiroz C, et al. Dopaminergic hypersensitivity of the opioid-responsive striatal–entopeduncular pathway in a rodent model of restless legs syndrome. Neuropsychopharmacology. 2026. doi:10.1038/s41386-026-02413-2